Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CKD-349 vs D113 (Entresto) in Healthy Volunteers
NCT05089279Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sacubitril and valsartan in heart failure (HF) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the last measurable concentration and Maximum Plasma Concentration. Started Nov 2021; status: completed.
02
Drugs
sacubitrilvalsartan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05089279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05089279.